Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, 3912 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, 3912 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA.
Clin Liver Dis. 2020 Nov;24(4):577-590. doi: 10.1016/j.cld.2020.07.001. Epub 2020 Aug 28.
Hepatocellular carcinoma (HCC) is increasing in prevalence and is the third leading cause of cancer-related death worldwide. Unlike other malignancies, HCC can be diagnosed with dynamic imaging with very high accuracy, and tissue diagnosis is not needed for cancer therapy. There is a unique role of established as well as developing biomarkers in diagnosis, prognosis, and management of HCC. Sequencing HCC tumors has yielded substantial insights into HCC tumor biology and has raised the possibility of precision oncology in which therapy decisions are guided by cancer genetics. However, it is not ready for prime time yet.
肝细胞癌（HCC）的发病率正在上升，是全球癌症相关死亡的第三大主要原因。与其他恶性肿瘤不同，HCC 可以通过动态成像进行非常准确的诊断，并且不需要组织诊断来进行癌症治疗。已建立和正在开发的生物标志物在 HCC 的诊断、预后和管理中具有独特的作用。对 HCC 肿瘤进行测序为 HCC 肿瘤生物学提供了大量的见解，并提出了精准肿瘤学的可能性，即根据癌症遗传学指导治疗决策。然而，它还没有准备好投入使用。
